Better systems, not guidelines, for glucose monitoring

BMJ 2004; 329 doi: http://dx.doi.org/10.1136/bmj.329.7479.E332 (Published 9 December 2004)
Cite this as: BMJ 2004;329:E332

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Paris Roach (paroach@iupui.edu), associate professor of clinical medicine1
  1. 1 Division of Endocrinology and Metabolism Indiana University School of Medicine 545 Barnhill Drive, Emerson Hall Room 421 Indianapolis, IN 46202

    Reynolds and Strachan propose that routine home blood glucose monitoring (HBGM) not be used to monitor non-insulin treated patients with type 2 diabetes due to lack of evidence of its benefit. Their underlying concerns are that unnecessary HBGM will result in unjustified costs and that it may adversely affect patients' quality of life. They also suggest that large randomized trials be performed to provide guidance on the optimal use of HBGM in this population.

    The effectiveness of any glucose monitoring program is highly dependent on the ability …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL